| Jun'18 | Mar'18 | Dec'17 | Sep'17 | Jun'17 | Mar'17 | Dec'16 | Sep'16 | Jun'16 | Mar'16 |
|---|---|---|---|---|---|---|---|---|---|
IPO [Member] | |||||||||
Private Placement [Member] | |||||||||
Operating activities: | |||||||||
Net loss | |||||||||
-60,669 | -62,757 | -96,388 | -83,790 | -69,540 | -58,348 | -12,545 | 0 | 0 | 0 |
Adjustments to reconcile net loss to net cash from operating activities: | |||||||||
Research and development expense settled by shares issuance | |||||||||
0 | 0 | 42,259 | 42,259 | 42,259 | 42,259 | 0 | 0 | 0 | 0 |
Share-based compensation | |||||||||
19,120 | 26,884 | 22,683 | 0 | 0 | 0 | - | - | - | - |
Depreciation expense | |||||||||
39 | 38 | 32 | 26 | 22 | 19 | 18 | 0 | 0 | 0 |
Changes in operating assets and liabilities: | |||||||||
Advances to suppliers | |||||||||
559 | 548 | 726 | 1,266 | 1,072 | 806 | 710 | 0 | 0 | 0 |
Government grants | |||||||||
0 | 0 | - | - | 0 | 0 | - | - | - | - |
Prepaid expenses | |||||||||
- | - | - | - | - | - | - | 0 | 0 | 0 |
Other current assets | |||||||||
- | - | - | - | - | - | - | 0 | 0 | 0 |
Prepaid expenses and other current assets | |||||||||
0 | 0 | - | - | 0 | 0 | - | - | - | - |
Other noncurrent assets | |||||||||
373 | 280 | 240 | 190 | 178 | 176 | 121 | 0 | 0 | 0 |
Accounts payable | |||||||||
774 | 3,377 | 2,935 | -416 | 738 | 597 | 144 | 0 | 0 | 0 |
Accrued expenses | |||||||||
1,342 | 1,101 | 699 | 1,071 | 582 | -79 | -102 | 0 | 0 | 0 |
Amounts due to related parties | |||||||||
-2 | -7 | -210 | -362 | -410 | -401 | -222 | 0 | 0 | 0 |
Other current liabilities | |||||||||
169 | 142 | 64 | 340 | 270 | 97 | 174 | 0 | 0 | 0 |
Net cash used in operating activities | |||||||||
-40,426 | -32,456 | -28,796 | 0 | 0 | 0 | - | - | - | - |
Investing activities: | |||||||||
Net cash used in operating activities | |||||||||
- | - | - | - | - | - | - | - | 0 | 0 |
Acquisitions of property and equipment | |||||||||
69 | 75 | 76 | 43 | 50 | 78 | 64 | 0 | 0 | 0 |
Net cash used in investing activities | |||||||||
-3,143 | -3,149 | -3,150 | 0 | 0 | 0 | - | - | - | - |
Financing activities: | |||||||||
Net cash used in investing activities | |||||||||
- | - | - | - | - | - | - | - | 0 | 0 |
Proceeds from issuance of ordinary shares, net of underwriting discount | |||||||||
14,000 | 0 | 50,505 | 50,505 | 65,755 | 65,755 | 15,250 | 0 | 0 | 0 |
Payment of offering costs | |||||||||
- | 449 | - | - | - | 2,829 | 537 | 0 | 0 | 0 |
Net cash provided by financing activities | |||||||||
13,829 | -449 | 47,722 | 0 | 0 | 0 | - | - | - | - |
Effect of foreign exchange rate changes, net | |||||||||
173 | -160 | 18 | 0 | 0 | 0 | - | - | - | - |
Net cash (used in) provided by financing activities | |||||||||
- | - | - | - | - | - | - | - | 0 | 0 |
Effect of foreign exchange rate changes, net | |||||||||
- | - | - | - | - | - | - | - | 0 | 0 |
Net increase/(decrease) in cash | |||||||||
-29,567 | -36,214 | 15,794 | 20,389 | 43,348 | 45,769 | 866 | 0 | 0 | 0 |
Non-cash activities: | |||||||||
Initial public offering costs accrued in accrued expenses and other current liabilities | |||||||||
- | - | - | - | - | - | 1,324 | 0 | 0 | 0 |
Research and development expense settled by shares issuance | |||||||||
0 | 0 | 42,259 | 42,259 | 42,259 | 42,259 | 0 | 0 | 0 | 0 |